Synthetic cannabis: A comparison of patterns of use and effect profile with natural cannabis in a large global sample

Drug and Alcohol Dependence

Volumn 131, Issue 1-3, 2013, Pages 106-111

  Winstock, Adam R ^a,b   Barratt, Monica J ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Global Drug Survey   (United Kingdom)

^c CURTIN UNIVERSITY   (Australia)

Author keywords

Cannabis; Epidemiology; Online survey; Synthetic cannabinoids

Indexed keywords

CANNABIS; CANNABIS DERIVATIVE; SYNTHETIC CANNABIS; UNCLASSIFIED DRUG;

ARTICLE; CANNABIS ADDICTION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG USE; FEMALE; HANGOVER; HUMAN; MALE; ONLINE SYSTEM; PARANOIA; PLEASURABLE EFFECT; PRIORITY JOURNAL; SELF REPORT;

ADULT; CANNABINOIDS; CHOICE BEHAVIOR; DATA COLLECTION; FEMALE; HUMANS; INTERNATIONALITY; MALE; MARIJUANA SMOKING; PLEASURE; TIME FACTORS; YOUNG ADULT;

CANNABIS;

EID: 84878586179     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2012.12.011     Document Type: Article

References (43)

1. Advisory Council on the Misuse of Drugs Consideration of the Major Cannabinoid Agonists 2009, Home Office, London.
2. Barratt M.J., Cakic V., Lenton S. Patterns of synthetic cannabinoid use in Australia. Drug Alcohol Rev. 2012, 10.1111/j.1465-3362.2012.00519.x.
3. Brown K. New Zealand bans synthetic cannabinoids. BMJ 2011, 343:d5395.
4. Castellanos D., Singh S., Thornton G., Avila M., Moreno A. Synthetic cannabinoid use: a case series of adolescents. J. Adolesc. Health 2011, 49:347-349.
5. Castellanos D., Thornton G. Synthetic cannabinoid use: recognition and management. J. Psychiatr. Pract. 2012, 18:86-93.
6. Dargan P.I., Hudson S., Ramsey J., Wood D.M. The impact of changes in UK classification of the synthetic cannabinoid receptor agonists in 'Spice'. Int. J. Drug Policy 2011, 22:274-277.
7. de Havenon A., Chin B., Thomas K.C., Afra P. The secret " spice" : an undetectable toxic cause of seizure. Neurohospitalist 2011, 1:182-186.
8. de Jager A.D., Warner J.V., Henman M., Ferguson W., Hall A. LC-MS/MS method for the quantitation of metabolites of eight commonly-used synthetic cannabinoids in human urine-an Australian perspective. J. Chromatogr. B 2012, 897:22-31.
9. European Monitoring Centre for Drugs and Drug Addiction 2010 Annual Report on the State of the Drugs Problem in Europe 2010, EMCDDA, Luxembourg.
10. Evans-Brown M., Bellis M.A., McVeigh J. Should " legal highs" be regulated as medicinal products?. BMJ 2011, 342:501.
11. Every-Palmer S. Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Drug Alcohol Depend. 2011, 117:152-157.
12. Fattore L., Fratta W. Beyond THC: the new generation of cannabinoid designer drugs. Front. Behav. Neurosci. 2011, 5:60.
13. Fernandez M.C., Roth B., Villareal C.L. Fake marijuana causing real problems in Texas. Clin. Toxicol. 2011, 49:212.
14. Forrester M.B., Kleinschmidt K., Schwarz E., Young A. Synthetic cannabinoid exposures reported to Texas Poison Centers. J. Addict. Dis. 2011, 30:351-358.
15. Hammersley R. Dangers of banning spice and the synthetic cannabinoid agonists. Addiction 2010, 105:373.
16. Hoyte C.O., Jacob J., Monte A.A., Al-Jumaan M., Bronstein A.C., Heard K.J. A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010. Ann. Emerg. Med. 2012, 60:435-438.
17. Hudson S., Ramsey J. The emergence and analysis of synthetic cannabinoids. Drug Test Anal. 2011, 3:466-478.
18. Hughes B., Winstock A.R. Controlling new drugs under marketing regulations. Addiction 2012, 107:1894-1899.
19. McCambridge J., Hunt N., Winstock A., Mitcheson L. Has there been a decline in the prevalence of cannabis use among British nightclubbers? Five-year survey data. Drug Educ. Prev. Policy 2005, 12:167-169.
20. McCambridge J., Mitcheson L., Winstock A., Hunt N. Five-year trends in patterns of drug use among people who use stimulants in dance contexts in the United Kingdom. Addiction 2005, 100:1140-1149.
21. McCambridge J., Winstock A., Hunt N., Mitcheson L. 5-Year trends in use of hallucinogens and other adjunct drugs among UK dance drug users. Eur. Addict. Res. 2007, 13:57-64.
22. Möller I., Wintermeyer A., Bender K., Jübner M., Thomas A., Krug O., Schänzer W., Thevis M. Screening for the synthetic cannabinoid JWH-018 and its major metabolites in human doping controls. Drug Test Anal. 2011, 3:609-620.
23. Penny K.I., Atkinson I. Approaches for dealing with missing data in health care studies. J. Clin. Nurs. 2012, 21:2722-2729.
24. Rosenbaum C., Carreiro S., Babu K. Here today, gone tomorrow...and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, salvia divinorum, methoxetamine, and piperazines. J. Med. Toxicol. 2012, 8:15-32.
25. Schep L.J., Slaughter R.J., Temple W.A., Nair S.M., Gee P. Synthetic cannabinoid analogues-not repeating past mistakes. N. Z. Med. J. 2011, 124:85-86.
26. Schifano F., Corazza O., Deluca P., Davey Z., Di Furia L., Farre M., Flesland L., Mannonen M., Pagani S., Peltoniemi T., Pezzolesi C., Scherbaum N., Siemann H., Skutle A., Torrens M., Van Der Kreeft P. Psychoactive drug or mystical incense? Overview of the online available information on Spice products. Int. J. Cult. Ment. Health 2009, 2:137-144.
27. Schneir A.B., Baumbacher T. Convulsions associated with the use of a synthetic cannabinoid product. J. Med. Toxicol. 2012, 8:62-64.
28. Sobolevsky T., Prasolov I., Rodchenkov G. Detection of JWH-018 metabolites in smoking mixture post-administration urine. Forensic Sci. Int. 2010, 200:141-147.
29. Therapeutic Goods Administration (TGA) Final Decisions and Reasons for Decisions by Delegates of the Secretary to the Department of Health and Ageing 2012, Commonwealth of Australia, Canberra.
30. United Nations Office on Drugs and Crime Synthetic Cannabinoids in Herbal Products 2011, United Nations Office on Drugs and Crime, Vienna.
31. Vandrey R., Dunn K.E., Fry J.A., Girling E.R. A survey study to characterize use of Spice products (synthetic cannabinoids). Drug Alcohol Depend. 2012, 120:238-241.
32. Vardakou I., Pistos C., Spiliopoulou C. Spice drugs as a new trend: mode of action, identification and legislation. Toxicol. Lett. 2010, 197:157-162.
33. Warhaft G. Not for human consumption? The banning of synthetic cannabinoids. Of Subst. 2011, 9:14-17.
34. Wells D.L., Ott C.A. The " new" marijuana. Ann. Pharmacother. 2011, 45:414-417.
35. Westerbergh J., Hultèn P. Novel synthetic cannabinoids, CRA13, JWH-015, JWH-081 and JWH-210-detected in a case series. Clin. Toxicol. 2011, 49:222.
36. Winstock A., Mitcheson L., Ramsey J., Davies S., Puchnarewicz M., Marsden J. Mephedrone: use, subjective effects and health risks. Addiction 2011, 106:1991-1996.
37. Winstock A.R., Griffiths P., Stewart D. Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug Alcohol Depend. 2001, 64:9-17.
38. Winstock A.R., Marsden J., Mitcheson L. What should be done about mephedrone?. BMJ 2010, 340:1605.
39. Winstock A.R., Mitcheson L., Gillatt D.A., Cottrell A.M. The prevalence and natural history of urinary symptoms among recreational ketamine users. BJU Int. 2012, 110:E164-E165.
40. Winstock A.R., Mitcheson L.R., Deluca P., Davey Z., Corazza O., Schifano F. Mephedrone, new kid for the chop?. Addiction 2011, 106:154-161.
41. Winstock A.R., Ramsey J.D. Legal highs and the challenges for policy makers. Addiction 2010, 105:1685-1687.
42. Winstock A.R., Wolff K., Ramsey J. 4-MTA: a new synthetic drug on the dance scene. Drug Alcohol Depend. 2002, 67:111-115.
43. Zimmermann U.S., Winkelmann P.R., Pilhatsch M., Nees J.A., Spanagel R., Schulz K. Withdrawal phenomena and dependence syndrome after the consumption of " spice gold" . Deutsches Arzteblatt 2009, 106:464-467.